Whenever you need heart rate and rhythm information, KardiaMobile 6L helps you get the clarity you need quickly and easily. With wide-ranging use cases from detecting atrial fibrillation to monitoring QT in clinical research and beyond, KardiaMobile 6L is trusted by leading cardiologists, top biopharma companies, large CROs, Fortune 100 employers, and major healthcare systems.
The first FDA-cleared, 6-lead personal ECG device.
In just 30 seconds, KardiaMobile 6L provides access to a high-quality, 6-lead ECG without the hassle of wires, patches, or gels – making it easy for patients in the home or the office.
Ideal for capturing a quick ECG at an office visit or for extended remote monitoring, the easy-to-use KardiaMobile 6L provides flexibility to diagnose and treat patients.
Designed for clinicians to record and view ECGs efficiently at point-of-care. Triage patients in minutes with a HIPAA-compliant, SOC-2 certified system.
Designed for patients and clinical trial participants to record ECGs easily from home. Data are securely and automatically transmitted, enabling timely professional review of rate and rhythm information.
he world’s leading cardiologists use KardiaMobile, the most clinically validated personal ECG brand with over 185 clinical publications. Learn how KardiaMobile 6L can help you better treat your patients.
Randomized controlled trial, REHEARSE-AF, evaluated AFib detection of KardiaMobile vs. routine care in over 1,000 patients with 2x weekly ECGs over 12 months (or if symptomatic).
Estimated AFib detection probabilities of KardiaMobile ECG monitoring vs Routine Care over 52 weeks. Shaded area = 95% confidence (P=0.004).
Streamline QT interval monitoring with an accurate measurement in only 30 seconds for QT-prolonging medications.
250+ medications known to prolong QT intervals4
KardiaMobile 6L accurately measures QT intervals5
Leverages FDA-cleared algorithm for QT interval measurement
KardiaMoblie 6L was used post-TAVR with consecutive patients to monitor for delayed conduction disease in an elderly population (average age 81.8) for one month.1 Patients were trained on the device and submitted ECGs daily for the 1st week and weekly thereafter.
96.5% successful ECG submission
98.4% of ECGs were of adequate quality for diagnosis & interval measurement
Patients were very satisfied with KardiaMobile (4.6 out of 5)
Study findings suggest that KardiaMobile 6L provides a clinical benefit with higher accuracy compared to single-lead smartwatch devices when reviewed by a cardiologist.
KardiaMobile demonstrated better detection of AFib and Sinus Rhythm
~2x more accurate detection of Atrial Flutter
Preferred by Cardiologists
Founder and Director Scripps Research Translational Institute, and author of the new book, Deep Medicine
Dr. Topol has no financial relationship with or research support from AliveCor.
KardiaMobile 6L is not tested or recommended for use with pacemakers and ICDs. KardiaMobile 6L does not check for heart attack.
For compatibility information, visit alivecor.com/compatibility.
1. De Lucia R, et al. Europace (2023) 25, 116-1125.
2. Wong KC et al. Heart. 2020 Aug;106(16):1211-1217.
3. Halcox, JPJ et al. Circulation vol. 136,19 (2017): 1784-1794.
4. Woosley RL, Heise CW, Gallo T, Woosley D and Romero KA, www.CredibleMeds.org, QTdrugs List, September 13, 2023
5. JR et al. Circulation. 2021 Mar 30;143(13):1274-1286.
6. Scholten J et al. Am Heart J. 2022 Nov;253:53-58.
Don't hesitate to contact us via email or phone to learn more.
Email: enquiry@mellica.com
Phone: +852 34695611
Kardia 12L
